According to Whosaeng News, REV-MED is emerging as one of the key beneficiaries following the implementation of the amended “Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety Act” (commonly referred to as the “Advanced Regenerative Medicine Act” or “첨생법”).
The amendment is expected to create significant opportunities for REV-MED’s autologous biological extraction technologies and bio-kit products, enabling the company to expand sales not only in Korea but also in global markets due to the lowered regulatory barriers.
REV-MED (CEO Edward BG Shin) recently announced that it plans to actively expand its business scope by leveraging the broadened clinical research targets and simplified approval procedures introduced through the revised legislation.
A key aspect of the amendment is the expansion of advanced regenerative medicine applications beyond severe, rare, and intractable diseases to include general medical conditions.
This regulatory change is expected to highlight the value of REV-MED’s independently developed autologous biological extraction technologies. The company has already established a state-of-the-art cell processing facility at its new headquarters, demonstrating its strong commitment to leading the regenerative medicine field. In addition, REV-MED’s proprietary triple-chamber technology, developed for biological processing applications, has obtained certifications in both Japan and China.
REV-MED has also successfully developed a range of bio-kits capable of extracting cells from various tissues including blood, bone marrow, and adipose tissue. Its contamination-prevention design has been recognized in the global market for its reliability and safety.
These technological capabilities are expected to accelerate the company’s growth in line with the expanded approval pathways for clinical and therapeutic use enabled by the revised law.
In particular, REV-MED’s autologous biological extraction technologies and bio-kit product portfolio are anticipated to become major beneficiaries of the regulatory reform. The amendment now allows limited patient administration through treatment-purpose approval procedures during the clinical stage, creating opportunities for revenue generation even in the early phases of research.
REV-MED has published approximately 20 SCI(E)-level papers related to these technologies, further strengthening its credibility in the global scientific community. The company has designated this year as the “first year of global expansion” and is focusing on expanding into European and Asian markets.
A REV-MED representative stated, “This amendment to the Advanced Regenerative Medicine Act represents a major turning point that will create new growth opportunities for Korea’s regenerative medicine market. We are fully prepared to lead this transformation.”
The representative added, “Based on our proprietary technologies and infrastructure, we will continue strengthening our competitiveness in the global biological products market while striving to provide innovative therapeutic solutions.”
According to Whosaeng News, REV-MED is emerging as one of the key beneficiaries following the implementation of the amended “Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety Act” (commonly referred to as the “Advanced Regenerative Medicine Act” or “첨생법”).
The amendment is expected to create significant opportunities for REV-MED’s autologous biological extraction technologies and bio-kit products, enabling the company to expand sales not only in Korea but also in global markets due to the lowered regulatory barriers.
REV-MED (CEO Edward BG Shin) recently announced that it plans to actively expand its business scope by leveraging the broadened clinical research targets and simplified approval procedures introduced through the revised legislation.
A key aspect of the amendment is the expansion of advanced regenerative medicine applications beyond severe, rare, and intractable diseases to include general medical conditions.
This regulatory change is expected to highlight the value of REV-MED’s independently developed autologous biological extraction technologies. The company has already established a state-of-the-art cell processing facility at its new headquarters, demonstrating its strong commitment to leading the regenerative medicine field. In addition, REV-MED’s proprietary triple-chamber technology, developed for biological processing applications, has obtained certifications in both Japan and China.
REV-MED has also successfully developed a range of bio-kits capable of extracting cells from various tissues including blood, bone marrow, and adipose tissue. Its contamination-prevention design has been recognized in the global market for its reliability and safety.
These technological capabilities are expected to accelerate the company’s growth in line with the expanded approval pathways for clinical and therapeutic use enabled by the revised law.
In particular, REV-MED’s autologous biological extraction technologies and bio-kit product portfolio are anticipated to become major beneficiaries of the regulatory reform. The amendment now allows limited patient administration through treatment-purpose approval procedures during the clinical stage, creating opportunities for revenue generation even in the early phases of research.
REV-MED has published approximately 20 SCI(E)-level papers related to these technologies, further strengthening its credibility in the global scientific community. The company has designated this year as the “first year of global expansion” and is focusing on expanding into European and Asian markets.
A REV-MED representative stated, “This amendment to the Advanced Regenerative Medicine Act represents a major turning point that will create new growth opportunities for Korea’s regenerative medicine market. We are fully prepared to lead this transformation.”
The representative added, “Based on our proprietary technologies and infrastructure, we will continue strengthening our competitiveness in the global biological products market while striving to provide innovative therapeutic solutions.”